Holen Sie sich die Stockscreener-App
27.64
0.20%
-0.005
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Is Alkermes (ALKS) Pricing In Its Potential After Recent Share Price Weakness - Yahoo Finance UK
Market Outlook: Will Alkermes plc outperform its industry peers2026 Summary & Long-Term Growth Plans - baoquankhu1.vn
Victory Capital Management Inc. Has $10.33 Million Stock Position in Alkermes plc $ALKS - MarketBeat
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program - The Joplin Globe
Opioid Use Disorder Market Booming with Rapid Growth Through 2033 | Indivior PLC • Alkermes • Orexo AB - openPR.com
Alkermes to Present at the Stifel 2026 Virtual CNS Forum - BioSpace
Alkermes shares rise after revenue beat and upbeat outlook offsets earnings miss - MSN
Citigroup Inc. Sells 121,945 Shares of Alkermes plc $ALKS - MarketBeat
Is Alkermes’ Slower Q4 and CEO Transition Reshaping Its Orexin Strategy and Investment Case (ALKS)? - Sahm
Rhenman & Partners Asset Management AB Buys 55,000 Shares of Alkermes plc $ALKS - MarketBeat
Neuberger Berman Group LLC Has $4.58 Million Holdings in Alkermes plc $ALKS - MarketBeat
Alkermes Advances ALKS 2680 Into Phase 3 for Narcolepsy Type 1: What Investors Should Watch - TipRanks
Alkermes plc (NASDAQ:ALKS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
(ALKS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - Stocktwits
Alkermes (NASDAQ:ALKS) EVP Sells $59,575.86 in Stock - MarketBeat
Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat
Christian Todd Nichols Sells 6,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat
TD Asset Management Inc Sells 91,772 Shares of Alkermes plc $ALKS - MarketBeat
2,034-share Rule 144 sale by Alkermes insider (NASDAQ: ALKS) - Stock Titan
ALKS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Celebrating LGBTQIA+ Mental Health Trailblazers - CSRwire
Alkermes Reports 2025 Financials, Advances Narcolepsy Pipeline, Announces CEO Succession - Sleep Review
Alkermes Pivots Deeper Into Sleep Medicine After Avadel Deal, Details Orexin Phase 3 at TD Cowen - Yahoo Finance
Alkermes (NASDAQ: ALKS) insider sells common stock via Form 144 - Stock Titan
Alkermes (ALKS) Rule 144: Insider sale notice for 6,000 shares, $180K - Stock Titan
5,000-share exercise and multiple sales reported by Alkermes (ALKS) - Stock Titan
Alkermes at TD Cowen: Strategic Shift to Sleep Medicine - Investing.com
Alkermes Plc (ALKS) Stock Analysis: Exploring A 45% Potential Upside In Biopharma - DirectorsTalk Interviews
American Century Companies Inc. Purchases 740,248 Shares of Alkermes plc $ALKS - MarketBeat
Alkermes Releases Third Annual Corporate Responsibility Report - CSRwire
ALKSAlkermes plc Reports Results for Fiscal 2012 and Provides Expectations for Fiscal 2013 - mx.advfn.com
Alkermes plc $ALKS Shares Bought by Artisan Partners Limited Partnership - MarketBeat
Alkermes (ALKS) VP exercises RSUs and withholds 808 shares for tax - Stock Titan
Alkermes (ALKS) CCO logs RSU exercise and tax share withholding - Stock Titan
Alkermes (ALKS) COO logs RSU share gain and tax-related share disposal - Stock Titan
Alkermes (ALKS) EVP Hopkinson converts 6,866 RSUs, withholds 3,049 shares for taxes - Stock Titan
Alkermes (ALKS) EVP Gaffin exercises RSUs, withholds 3,049 shares for tax - Stock Titan
Alkermes’ ALKS 2680 Narcolepsy Study Completion: What Investors Should Watch Next - TipRanks
Alkermes plc $ALKS Shares Sold by Primecap Management Co. CA - MarketBeat
H.C. Wainwright lowers Alkermes stock price target on revenue guidance By Investing.com - Investing.com Canada
4 Analysts Have This To Say About Alkermes - Benzinga
Wells Fargo Boosts Price Target for Alkermes (ALKS), Maintains O - GuruFocus
Harris Poll Survey Offers Insights into Potential of Telepsychiatry During and After the COVID-19 Pandemic - CSRwire
ALKS: RBC Capital Adjusts Price Target; Maintains Outperform Rat - GuruFocus
Royal Bank Of Canada Has Lowered Expectations for Alkermes (NASDAQ:ALKS) Stock Price - MarketBeat
Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change - Zacks Investment Research
Alkermes Reveals CEO Succession Plan Following Richard Pops’ Retirement Announcement - Pharmaceutical Executive
RBC Lowers Price Target on Alkermes to $45 From $47, Keeps Outperform Rating - marketscreener.com
Alkermes plc (NASDAQ:ALKS) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright lowers Alkermes stock price target on revenue guidance - Investing.com
Alkermes Plc earnings missed by $0.12, revenue topped estimates - Investing.com Australia
Decoding Alkermes PLC (ALKS): A Strategic SWOT Insight - GuruFocus
Alkermes CEO Richard Pops to retire after 35 years, Jackson named successor - Investing.com Nigeria
Alkermes plc 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ALKS) 2026-02-25 - Seeking Alpha
Alkermes FY 2025 presentation: transition year sets stage for growth By Investing.com - Investing.com Australia
Alkermes Earnings Call: Growth, LUMRIZE and New Risks - TipRanks
Does Alkermes’ Weaker 2025 Results and CEO Changeover Shift the Bull Case for ALKS? - Yahoo Finance
Alkermes (ALKS) CCO converts 6,407 RSUs, withholds 2,845 shares for tax - Stock Titan
Alkermes (NASDAQ: ALKS) COO exercises RSUs, shares withheld for tax - Stock Titan
[Form 4] Alkermes plc. Insider Trading Activity - Stock Titan
S&E In Brief: Commercial Updates From The SMID Cap Universe - Citeline News & Insights
Alkermes (ALKS) Announces CEO Transition as Shares Dip - GuruFocus
Alkermes PLC (ALKS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Alkermes (ALKS) Q4 2025 Earnings Call Transcript - The Globe and Mail
Is Alkermes (ALKS) Pricing In Its Neuroscience And Orexin Pipeline Potential? - simplywall.st
Alkermes Announces CEO Succession and Leadership Transition Plan - TipRanks
Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 - 富途牛牛
Alkermes PLC (ALKS) Q4 2025 Earnings Call Highlights: Strong Rev - GuruFocus
0.66%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):